newco make sens investor
keytruda concentr remain overhang
messag like financi engin strateg rational spin
newco view spin-off creat valu sharehold
creat new premier specialti pharmaceut compani focus women health
flexibl mobil newco cash flow valuation-sensit market
like women health pain dermatolog keytruda concentr risk remain
unresolv dont believ make issu challeng may
fact establish greater sens urgenc ramp compani new product pipelin
intern extern bd updat pt previous
first cut newco suggest new structur modestli dilut
accret increas stand-alon ep growth
spin newco good strategi like strategi spin legaci
product assum consensu declin offer
sharehold rather provid negoti like taxabl privat equiti
transact judg sharehold benefit directli highli tax-effici way
consist posit believ deal ep value-accret
forecast flattish newco ep forese futur get
low-single-digit sale growth would either requir hand-hold
 bring new strateg acquir target consolid
and/or pressur specialti pharma market may underappreci opportun
long-term one underappreci compon busi biosimilar growth
opportun opportun grow exist portfolio predominantli women
health product global key newco sale growth stori
opinion also expect proactiv busi develop bd fuel growth
expir implanon/nexplanon said get greater visibl
growth stori forecast declin sale busi go forward
oper effici debt paydown provid stabl ep
stand-alon opportun repurchas share realiz
annual cost effici recov nearli lost newco earn
estim post estim set cost would need recov
approxim see ep us guidanc decis spin
make sens given rel modest contribut strateg import
product increment cost separ put pressur
 offset potenti share repurchas compani estim
annual net synergi reach separ recov major
estim earn lost spin-off
estim newco premier specialti pharmaceut spin
sale low end
ev/ebitda premium specialti pharma like bhc
would peg market capit high end
one critiqu couldnt get valu busi via sale anoth
compani perhap privat equiti line suggest women health
gi busi case offer much bigger busi could
well broader intern busi cash flow potenti
effici gain justifi importantli run peak margin
either busi exactli make sens view believ
page analyst certif import disclosur
busi could evolv becom premier specialti pharma compani bring
import new strateg asset acquir year post spin
tabl ep impact newco remco spin-off detail
remainingco remco one key question remco concentr risk
keytruda view spin make futur bd much visibl impact
includ tuck-in deal equal import evolut intern
pipelin develop surprisingli slow pace one issu need
commun rel disappoint sale perform sever front
keytruda q/q growth see dramat slowdown gardasil contribut
given suppli constraint sequenti price cut japan februari
second similar cut expect april could temper keytruda ou sale
vs prior expect without china nrdl list
heavier burden develop market growth ex-japan
gardasil y/i declin predict sale still miss our/consensu
forecast larg due suppli constraint hope there increment capac
realiz least meet mid-single-digit growth assumpt
rel investor concern concentr risk problem may year prematur
keytruda still runaway least howev revenu forecast may
go fact take number ep go post believ
must absolut diversifi revenu base away keytruda debat
appropri multipl pay ex-newco
estim stand-alon remco worth
use ev/ebit regress assum mrk ep growth rate
goe one could argu trade
multipl novn mayb even approach youd look ebit
warrant stand-alon trade
market capit today basic could impli
sharehold get newco free
anoth approach might valu anim health vaccin newco see
your actual pay pharma busi
metric anim health vaccin probabl trade price-to-earnings
estim would repres valuat
 spec spin worth sale
 exclud mean remain estim net incom
investor get pharma busi
pay pharma ep question remain exactli one pay
keytruda huge percentag businessi
someth greater believ someth higher current stock price
warrant fulli acknowledg challeng face reset expect
around particular debat
potenti driver remco
wake rel disappoint question remain sale live
investor expect well posit beat guidanc
broadli keytruda believ good stock
month gardasil suppli start come compani start show
pipelin investor like well reward may near-
term bottom share stock could range-bound investor continu
persever import keytruda growth futur view
page analyst certif import disclosur
transform busi develop requir la decis acquir
dcf-base price target previous forecast sale
profit global pharma discount rate termin
downsid risk deceler gardasil growth neg keytruda readout
next month chang price environ oncolog drug
page analyst certif import disclosur
page analyst certif import disclosur
modelcagrcagr usd million except incom tax incom share incom incom growth profit global
page analyst certif import disclosur
incom million except per-shar expens total incom income/expens tax incom net inform dilut share ep compani report guggenheim secur llc estim global
page analyst certif import disclosur
incom million except per-shar figur revenu expens total incom income/expens tax incom inform dilut share ep compani report guggenheim secur llc estim global
issu research report guggenheim secur llc guggenheim secur research analyst whose name appear report
herebi certifi view express report accur reflect research analyst person view subject
secur issuer discuss herein ii part research analyst compens directli indirectli relat specif
recommend view express research analyst
research analyst whose name appear report receiv compens base upon variou factor includ qualiti research
investor client feedback guggenheim secur llc overal revenu includ invest bank revenu
guggenheim secur llc affili expect receiv intend seek compens invest bank servic merck co
inc next month
pleas refer websit company-specif disclosur referenc report http //guggenheimsecur bluematrix com/sellside/
disclosur action disclosur inform also avail complianc madison avenu new york ny
rate price target histori merck co inc
creat bluematrix
buy describ stock expect provid total return price appreci plu yield within period
neutral describ stock expect provid total return price appreci plu yield plu minu within
sell describ stock expect provid total neg return price appreci plu yield within period
nr invest rate price target temporarili suspend suspens complianc applic regul and/or
cs coverag suspend guggenheim secur llc suspend coverag compani
nc cover guggenheim secur llc cover compani
monitor describ stock whose compani fundament financi monitor financi project opinion
invest merit compani provid
review ur follow releas signific news compani rate temporarili place review suffici
inform obtain assess analyst
guggenheim secur llc methodolog assign rate may includ follow market capit matur growth/valu volatil
expect total return next month price target base sever methodolog may includ restrict analys
market risk growth rate revenu stream discount cash flow dcf ebitda ep cash flow cf free cash flow ev/ebitda price-to-earnings pe/growth
price-to-cf p/fcf premium discount /averag group ev/ebitda premium discount /averag group price-to-earnings sum part net asset valu dividend return
return equiti roe next month
price target assign buy- sell-rat stock price target neutral-r stock provid discret analyst
page analyst certif import disclosur
